Telomir Pharmaceuticals Inc（TELO）資訊與事件TELOTelomir Pharmaceuticals Inc

Selling Stockholders Plan to Sell Up to 5.29M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.29M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Telomir Pharmaceuticals Publishes New Research Showing Telomir-Zn Improves Visual Function

Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration. The findings extend the scientific understanding of Telomir-Zn beyond oncology, providing new evidence that modulation of intracellular metal homeostasis may influence disease-associated pathways across substantially different biological settings. In the AMD model, Telomir-Zn improved visual performance and retinal structure and was associated with restoration of altered DNA methylation patterns and a dose-dependent increase in relative telomeric DNA content toward the profile observed in healthy animals. Complementary mechanistic studies showed that Telomir-Zn reduced intracellular labile iron and potently inhibited iron-dependent Jumonji C histone demethylases, enzymes that help regulate which genes cells turn on or off. The findings provide a potential mechanistic link between Telomir-Zn's effects on intracellular metals and its emerging role in epigenetic regulation. In retinal degeneration, this biology may be particularly relevant to cellular programs involved in inflammation, senescence, DNA repair, and survival as retinal cells respond to oxidative and mitochondrial stress. Telomir's clinical development remains focused on oncology, with Telomir-Zn advancing under an FDA-cleared Investigational New Drug application for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. The new retinal findings add to a growing body of published research supporting a common upstream biology centered on intracellular metal homeostasis and epigenetic regulation, while demonstrating that the biological relevance of Telomir-Zn may extend beyond the Company's current clinical development focus.

Telomir Pharmaceuticals' Telomir-Zn Approved by FDA

Telomir Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer, TNBC.